Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

AntlerA Therapeutics

Ownership
Private
Employees
~50
Therapeutic Areas
OphthalmologyGastroenterologyRheumatology
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Protein therapeuticsAntibody-like moleculesBispecific antibodyMonoclonal antibody

AntlerA Therapeutics General Information

AntlerA has developed a Norrin/Wnt-mimetic antibody (EYE103) that has entered clinical trials through a partnership with EyeBio for treatment of retinopathies. Their lead candidate ANT-39 targeting FZD4 for retinal diseases has reached IND Application stage.

Contact Information

Website
https://www.prnewswire.com/news/antlera-therapeutics%2C-inc./
Primary Industry
Biotech
Corporate Office
Toronto, Ontario
Canada

Drug Pipeline

Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to AntlerA Therapeutics's pipeline data

Book a demo

Key Partnerships

EyeBio, Genentech/Roche

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

AntlerA Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view AntlerA Therapeutics's complete valuation and funding history, request access »

AntlerA Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals